Welcome to the e-CCO Library!

DOP77: Is durable remission achievable after ileocolic resection for Crohn's disease ? Long-term results of a prospective multicentric cohort study of the GETAID Chirurgie
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Abdalla, S.(1)*;Benoist, S.(1);Maggiori, L.(2);Lefevre, J.(3);Denost, Q.(4);Cotte, E.(5);Germain, A.(6);Beyer-Berjot, L.(7);Desfourneaux, V.(8);Rahili, A.(9);Duffas, J.P.(10);Pautrat, K.(11);Denet, C.(12);Bridoux, V.(13);Meurette, G.(14);Faucheron, J.L.(15);Loriau, J.(16);Souche, F.R.(17);Corte, H.(2);Zerbib, P.(18);Panis, Y.(19);Brouquet, A.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP77: Mesenchymal stem cell therapy for refractory Crohn’s perianal fistulas: a case series
Year: 2024
Source: ECCO'24 Stockholm
Authors: Pronk, Annelies
Created: Tuesday, 30 April 2024, 5:03 PM
DOP77: The effectiveness of combination therapy mesenchymal stromal cells and certolizumab pegol in perianal lesions in Crohn's disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

O. Knyazev1, A. Kagramanova*1, A. Lishchinskaya1, M. Zvyaglova1, D. Kulakov1, A. Parfenov1

Created: Friday, 22 February 2019, 9:41 AM
DOP78 Intestinal surgery rates in ulcerative colitis and Crohn’s disease in the era of biologics: A Danish Nationwide Register Study from 2003 to 2016
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. Vadstrup1, S. Alulis2, A. Borsi3, J. Olsen4, T.R. Jørgensen5, P. Munkholm6, N. Qvist7

Created: Thursday, 30 January 2020, 10:12 AM
DOP78: Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)
Year: 2022
Source: ECCO'22
Authors: García García, M.J.(1);Rivero, M.(1);Fernández-Clotet, A.(2);de Francisco, R.(3);Sicilia, B.(4);Mesonero, F.(5);de Castro, M.L.(6);Casanova, M.J.(7);Bertoletti, F.(8);García Alonso, F.J.(9);López García, A.(10);Julián, B.(11);Calvet, X.(12);Barreiro-de Acosta, M.(13);Jara, L.(14);Varela, P.(15);Nuñez, A.(16);Ricart, E.(2);Riestra, S.(3);Arias, L.(4);Rodríguez, M.(17);Arranz, L.(18);Pajares, R.(19);Mena, R.(20);Calafat, M.(21);Camo, P.(22);Jiménez, L.(23);Ponferrada, A.(24);Madrigal, R.E.(25);Llao, J.(26);Sesé, E.(27);Almela, P.(28);Codesido, L.(29);de la Maza, S.(30);Leal, C.(31);Sánchez, E.(5);Pineda Mariño, J.R.(6);Domènech, E.(21);Chaparro, M.(7);P. Gisbert, J.(7); GETECCU
Created: Friday, 11 February 2022, 3:52 PM
DOP78: Does KONO-S anastomosis reduce recurrence in Crohn's disease compared to conventional ileocolonic anastomosis ? A nationwide propensity score-matched study from GETAID Chirurgie Group (KoCoRICCO study).
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Alibert, L.(1);Betton, L.(2);Falcoz, A.(3);Manceau, G.(4);Benoist, S.(5);Zerbib, P.(6);Podevin, J.(7);Maggiori, L.(8);Brouquet, A.(5);Tyrode, G.(9);Vuitton, L.(9);Vernerey, D.(3);Lefevre, J.(2);Lakkis, Z.(1)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP78: Efficacy of vedolizumab in perianal Crohn’s disease: the BioLAP multi-centre observational study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Biron*1, P. Seksik2, M. Nachury3, S. Nancey4, Y. Bouhnik5, M. Serrero6, L. Armengol-Debeir7, A. Buisson8, M-L. Tran Minh9, C. Zallot10, M. Fumery11, G. Bouguen12, V. Abitbol13, S. Viennot14, E. Chanteloup15, S. Rajca16, N. Dib17, L. Peyrin-Biroulet10, L. Vuitton18

Created: Friday, 22 February 2019, 9:41 AM
DOP78: Efficacy of vedolizumab in perianal Crohn’s disease: the BioLAP multicenter observational study
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Constance Biron
Created: Tuesday, 28 May 2019, 3:32 PM
Vedolizumab, Perianal disease, Perianal disease
Files: 1
DOP78: The differential diagnosis and clinicopathological spectrum of Inflammatory Bowel Disease: An interesting and informative ECCO topical review
Year: 2021
Source: ECCO'21 Virtual
Authors: Feakins , R.M.(1); Torres, J.(2); Borralho-Nunes, P.(3,4); Burisch, J.(5); Cúrdia Gonçalves, T.(6,7,8); De Ridder, L.(9); Driessen, A.(10); Lobatón, T.(11); Menchén, L.(12,13,14); Mookhoek, A.(15); Noor, N.(16); Svrcek, M.(17); Villanacci, V.(18); Zidar, N.(19); Tripathi, M.(20)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP79 Dose escalation of upadacitinib in Crohn’s disease patients with an inadequate response: Data from the randomised CELEST study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W. Sandborn MD1, J. Panés2, L. Peyrin-Biroulet3, E. Louis4, S. Greenbloom5, W. Zhou6, Q. Zhou7, J. Liu8, A.P. Lacerda6

Created: Thursday, 30 January 2020, 10:12 AM
DOP79: Alternative polygenic forms of Inflammatory Bowel Disease are not captured by current generations of polygenic risk scores
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Beatriz Mateos
Created: Friday, 14 July 2023, 2:22 PM
DOP79: Alternative polygenic forms of Inflammatory Bowel Disease are not captured by current generations of polygenic risk scores
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mateos, B.(1)*;Gaite, A.(1);Rodríguez-Lago, I.(2);M. Marigorta, U.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP79: Biomarkers for IBD using OLINK Proteomics inflammation panel: Preliminary results from the COLLIBRI consortium
Year: 2022
Source: ECCO'22
Authors: Sudhakar, P.(1);Salomon, B.(2);Verstockt, B.(1,3);Ungaro, R.(4);Aden, K.(5); D'Haens, G.(6);Komori, K.(7);Guay, H.(8);Silverberg, M.(9);Vermeire, S.(1,3);Halfvarson, J.(10); The COLLIBRI consortium
Created: Friday, 11 February 2022, 3:52 PM
DOP79: Dose escalation of upadacitinib in Crohn’s Disease patients with inadequate response: Data from the randomised CELEST study
Year: 2020
Source: ECCO'20 Vienna
Authors: William Sandborn
Created: Tuesday, 23 June 2020, 5:40 PM